This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZGNX Zogenix (ZGNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zogenix Stock (NASDAQ:ZGNX) 30 days 90 days 365 days Advanced Chart Get Zogenix alerts:Sign Up Key Stats Today's Range$26.68▼$26.6850-Day Range$26.10▼$26.6852-Week Range$11.03▼$26.90Volume94 shsAverage Volume3.76 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Read More Receive ZGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter. Email Address ZGNX Stock News HeadlinesNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comMMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)Alcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 20, 2023 | morningstar.comMHow Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business WireOctober 11, 2022 | businesswire.comBiocryst PharmaceuticalsSeptember 30, 2022 | forbes.comNippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.comSeptember 26, 2022 | marketscreener.comMSee More Headlines ZGNX Stock Analysis - Frequently Asked Questions How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) announced its earnings results on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.08. The company's revenue for the quarter was up 690.6% compared to the same quarter last year. Read the conference call transcript. What other stocks do shareholders of Zogenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include Bristol Myers Squibb (BMY), QUALCOMM (QCOM), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Intel (INTC), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings11/04/2021Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZGNX CIK1375151 Webwww.zogenix.com Phone(510) 550-8300Fax858-259-1166Employees218Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.38 million Net Margins-278.38% Pretax Margin-278.26% Return on Equity-91.20% Return on Assets-43.60% Debt Debt-to-Equity Ratio0.88 Current Ratio3.63 Quick Ratio4.74 Sales & Book Value Annual Sales$81.69 million Price / Sales18.36 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book4.02Miscellaneous Outstanding Shares56,227,000Free Float53,922,000Market Cap$1.50 billion OptionableOptionable Beta0.89 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ZGNX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZGNX Stock Alerts